Mink Therapeutics Stock Today
| INKT Stock | USD 7.92 0.32 3.88% |
PerformanceOK
| Odds Of DistressHigh
|
Mink Therapeutics is selling for under 7.92 as of the 20th of March 2025; that is 3.88 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 7.8. Mink Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of October 2021 | Category Healthcare | Classification Health Care |
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases. The company has 3.96 M outstanding shares of which 30.68 K shares are currently shorted by private and institutional investors with about 0.43 trading days to cover. More on Mink Therapeutics
Moving together with Mink Stock
Moving against Mink Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Mink Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Jennifer Buell | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Biotech (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMink Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mink Therapeutics' financial leverage. It provides some insight into what part of Mink Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mink Therapeutics (INKT) is traded on NASDAQ Exchange in USA. It is located in 149 Fifth Avenue, New York, NY, United States, 10010 and employs 31 people. Mink Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 32.66 M. Mink Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.96 M outstanding shares of which 30.68 K shares are currently shorted by private and institutional investors with about 0.43 trading days to cover.
Mink Therapeutics currently holds about 29.85 M in cash with (15.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.88.
Check Mink Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Mink Therapeutics is $32.66 Million. Mink Therapeutics secures majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 74.83 % of Mink Therapeutics outstanding shares that are owned by insiders conveys that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Mink Ownership Details
Mink Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Tower Research Capital Llc | 2024-09-30 | 4 K | |
| Bank Of America Corp | 2024-09-30 | 2 K | |
| Advisor Group Holdings, Inc. | 2024-09-30 | 1.4 K | |
| Covestor Ltd | 2024-09-30 | 1 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 336 | |
| Jpmorgan Chase & Co | 2024-09-30 | 258 | |
| Northwestern Mutual Wealth Management Co | 2024-09-30 | 190 | |
| Game Plan Financial Advisors, Llc | 2024-09-30 | 170 | |
| Key Financial, Inc. | 2024-09-30 | 43.0 | |
| Vanguard Group Inc | 2024-09-30 | 234.2 K | |
| Longbow Finance Sa | 2024-09-30 | 166.7 K |
Mink Therapeutics Historical Income Statement
Mink Stock Against Markets
Mink Therapeutics Corporate Management
| Kimberly Ha | Head Relations | Profile | |
| Joy Zhou | Vice CMC | Profile | |
| Marcus Dijk | Chief Officer | Profile | |
| Heather Boussios | General Officer | Profile |
Additional Tools for Mink Stock Analysis
When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.